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Abstract
Engineered nanoparticles have the potential to expand the breadth of pulmonary therapeutics, 
especially as respiratory vaccines. Notably, cationic nanoparticles have been demonstrated to 
produce superior local immune responses following pulmonary delivery; however, the cellular 
mechanisms of this increased response remains unknown. To this end, we systematically 
investigated the cellular response of lung APCS following pulmonary instillation of anionic and 
cationic charged nanoparticles. While nanoparticles of both surface charges were capable of 
trafficking to the draining lymph node and were readily internalized by alveolar macrophages, 
both CD11b and CD103 lung dendritic cell (DC) subtypes preferentially associated with cationic 
nanoparticles. Instillation of cationic nanoparticles resulted in the upregulation of Ccl2 and Cxc10, 
which likely contributes to the recruitment of CD11b DCs to the lung. In total, these cellular 
mechanisms explain the increased efficacy of cationic formulations as a pulmonary vaccine carrier 
and provide critical benchmarks in the design of pulmonary vaccine nanoparticles.
Graphical Abstract
Nanoparticle surface charge is a key parameter in the recruitment and association of pulmonary 
antigen presenting cells following respiratory administration, resulting in increased cytokine and 
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chemokine production necessary for an effective lung vaccine. Pulmonary delivery of PRINT® 
cationic nanoparticles resulted in an increased local immune response and preferential association 
with dendritic cells compared to PRINT® anionic nanoparticle administration.
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INTRODUCTION
The next generation of vaccines can be achieved by pulmonary delivery of precision-
engineered particles (1-8). Engineered micro- and nanoparticles (NP) offer elegant solutions 
for pathogen mimicry, while providing increased safety and efficacy over current vaccine 
strategies (2, 3, 6). Additionally, engineered particles can be designed such that aerosol 
properties, lung deposition, and cellular interactions are independently taken into 
consideration (1, 2, 8, 9). While there is extensive literature describing how physical particle 
properties can influence aerodynamic diameter and thus pulmonary deposition, there is 
minimal understanding of how these same particle properties influence interactions with 
lung cells and their subsequent immune responses (1, 9).
Amongst the numerous cell types present in the lung, of particular interest to vaccine design 
are antigen presenting cells (APCs), which comprise B cells, dendritic cells (DCs) and 
macrophages (3, 10-15). Alveolar macrophages (AM), the main phagocytic cell in the lung, 
roam the airway epithelium, where they are responsible for internalizing, sequestering, and 
digesting any foreign material (12, 16-18). While they are generally considered APCs, their 
main function in the lung is more maintenance and clearance, rather than initiating adaptive 
responses (12, 17, 18). In contrast, lung DCs are considered “professional” APCs and act as 
a sentinel in the lung, monitoring and sampling foreign material to mount adaptive immune 
responses (3, 14, 15). Lung DCs are responsible for internalizing foreign particulates, 
digesting and presenting antigen by major histocompatibility complex (MHC) II, migrating 
to lymph nodes (LNs), and educating T cells (11-15, 19-21). In the lung, there are two 
conventional myeloid-derived DC subsets, CD11b and CD103 DCs, which have distinct 
functions (12, 14, 22). CD103 DCs protrude through the lung epithelium, are considered the 
main migratory population, and have been implicated in skewing the lung towards Th1, Th2 
and Th17 responses given different stimuli (12, 14, 16, 20-24). While CD11b DCs can also 
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migrate to the LNs, they have been shown to prime IgA production in the lung and are the 
major producers of soluble protein mediators, chemokines, and cytokines (11, 14, 16, 19, 23, 
24). These cells are found predominately under the basement membrane in the conducting 
airways (12). NP vaccination strategies capable of preferentially targeting these DCs 
subtypes, while avoiding inevitable AM uptake, are expected to result in superior responses.
Nanoparticles have been explored as pulmonary vaccine carriers, due to their potential to 
diffuse through mucosa, their avoidance of AMs, and their ability to co-deliver both 
adjuvants and antigens (3, 5-7, 10, 16, 25). To date, the role of NP charge on lung APC 
association remains poorly understood, as the majority of vaccination studies have focused 
on anionic NP carriers (4, 5). These formulations follow design principles of pathogen 
mimicry, as the majority of both bacteria and viruses have surfaces with acidic isoelectric 
points (26, 27). However, recent work from our group has demonstrated that pulmonary 
vaccination with cationic NPs can enhance local and systemic antibody production to a 
model antigen, as compared to otherwise equivalent anionic NPs (8). While these results 
indicate that nanoparticle charge is a key variable to immune responses in the lung, the 
underlying cellular mechanisms responsible for this deviation in immune response remain 
unclear. Understanding these lung processes is critical in the ultimate identification of NP 
design features capable of producing an optimized, controlled immune response.
As such, the goal of this work is to understand the cellular lung mechanisms involved in the 
processing of cationic and anionic NPs. We hypothesized that increased antibody production 
was the result of increased association of cationic NPs with lung DC subtypes, as well as a 
slight adjuvant effect of the charge associated with the NP itself. To further elucidate the role 
of nanoparticle surface charge on increased immune activity in the lung, we utilized the 
Particle Replication In Non-wetting Templates (PRINT) technique to fabricate hydrogel-
based NPs that varied only in surface charge and otherwise had identical size, shape and 
antigen loading. We investigate the role of NP charge on uptake by APCs, cytokine and 
chemokine recruitment, and subsequent trafficking of NPs to the mediastinal LNs in order to 
identify key cellular mechanisms involved in lung NP immune responses.
METHODS
Animals
All studies were conducted in accordance with National Institutes of Health guidelines for 
the care and use of laboratory animals and approved by the Institutional Animal Care and 
Use Committee (IACUC) at UNC. C57BL/6 (Jackson Laboratories) were maintained in 
pathogen-free facilities at UNC and used between 8-15 wks.
Nanoparticle Fabrication
Amine-containing 80 nm × 320 nm hydrogel rod-shaped (ζ+)NP were fabricated on a 
continuous roll-to-roll PRINT method as described previously (28) and in detail in 
Supplemental Methods. (ζ+)NPs in DMF were incubated with 100 M excess succinic 
anhydride for 30 minutes, washed first with borate buffer pH 9.5 and then three additional 
washes in water to achieve (ζ-)NP. Ovalbumin (OVA) functionalization was achieved using 
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water-soluble carboiimide chemistry, described previously (8) and in Supplemental 
Methods. NP characterization is described in Supplemental Methods.
Pulmonary Administration
NP and control formulations were delivered to the lungs of anesthetized mice through an 
orotracheal instillation in a 50 μL volume in PBS (8, 29). NP doses were 100 μg NP/mouse, 
corresponding to 10 μg OVA/mouse which was used as the control soluble OVA dose. In 
studies with adjuvant, 2.5 μg CpG/mouse or 20 μg LPS/mouse was delivered.
Biodistribution Study
Female, C57BL/6 mice (n=4) were dosed 88 μg of the respective nanoparticle (positive or 
negative 80 nm × 320 nm Dylight 650 hydrogels) orotracheally, as described above. As 
described detail within Supplemental Methods, blood and bronchoalveolar lavage fluid 
(BALF) were collected at 24 and 72 hrs with a single 1 mL PBS flush. Organs were then 
harvested for IVIS® Lumina optical imaging (Caliper Life Sciences, emission filter Cy5.5 
and excitation filter 640 nm) and radiant efficiency per gram was determined. Following 
harvest, lungs were dissociated into a single cell suspension, placed in TRIzol® (Invitrogen) 
and stored before extracting RNA for RT-qPCR.
Quantitative Real-Time PCR (qRT-PRC)
Mouse lungs from biodistribution study were used for qRT-PCR analysis. RNA isolation was 
performed from single cell suspensions of whole lung cells using TRIzol® (Invitrogen) 
followed by reverse transcription per standard protocol (30) and described in Supplemental 
Methods.
Antibodies: Flow Cytometry, ELISAs, and Histology
Single cell suspensions from tissues (see Supplemental Methods) were kept on ice and 
blocked with anti-CD16/32 (Fc block, eBioscience) and stained with the following 
antibodies to mouse cell surface molecules; I-A/I-E-PE-Cy7, CD11b-APC-Cy7, CD11c-PB, 
F4/80-PE-Cy5, CD45-BV510, CD103-PE, CD3-BV510, CD19-PE-Cy7, were from 
BioLegend. Cells were fixed using 2% PFA in PBS. All data were collected using LSRII 
(BD Biosciences) flow cytometer and analyzed using FlowJo software (Tree Star). Briefly, 
in the lung, macrophages and DCs were identified as CD45+CD11c+ populations and were 
separated by MHC II expression. MHC IIlo macrophages were confirmed to be F4/80+ and 
CD11b−. MHC IIhi DCs were further separated into a CD103+, CD11b− population, 
identifying the CD103 DCs, and a CD103−CD11b+ population of CD11b DCs. In the LN, T 
and B cells were identified as CD3+ and CD19+, while DCs were identified as 
CD3−CD19−CD11c+. The two DC subtypes were separated by CD103 and CB11b, as 
before. Representative gating for the lung and LN is shown in Supplemental Figures 1 and 5, 
respectively. Following population identification, each cell population was analyzed for NP 
fluorescence, gated by the PBS-treated, NP fluorescence-minus one (FMO) control (31). NP 
association was quantified as the percentage of each cell type which had a detectable signal 
in the NP channel. From the NP positive gate, the median fluorescence intensity (MFI) per 
cell was also determined.
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Enzyme-linked immunosorbent assay (ELISA) kits for IL-6, TNF-α, and IL-1β were 
purchased from BD Biosciences and used following manufacturer's suggestions on BALF 
and Serum samples. Preparation of lung histology is described in Supplemental Methods.
Statistical Analysis
Statistical analyses were performed with GraphPad Prism version 6. Analysis of groups was 
performed as indicated in figures, where asterisks indicating p values of *≤0.05, **≤0.01, 
***≤0.001 and n.s indicating not significant. NP batches, cell assays, and immunization 
studies were repeated in at least two independent experiments, with the number of replicates 
(NPs, cells, mice) indicated in figures.
RESULTS
Distribution of Cationic and Anionic Formulations in the Lung Following Pulmonary 
Instillation
In order to compare anionic and cationic NPs, we first quantified bulk organ distribution 
following pulmonary instillation in mice. Nanoparticles of (ζ+)NP and (ζ-)NP were 
fabricated as described previously (8) with the addition of a fluorescent dye to enable 
visualization throughout the organ tissue using an IVIS imaging system. Examples of lung 
fluorescence images are shown in Figure 1A. Organs were resected at 24 and 72 hrs to 
determine NP localization within this timeframe (Figure 1B). At both time points, NP 
fluorescence was detected above baseline in the lung and mediastinal lymph nodes, with no 
statistical difference between these groups. This indicated that NPs were mainly retained in 
the lung, with a detectable amount trafficking to the draining lymph node, even within 24 
hrs.
Lung pathology on mice receiving either (ζ+)NP or (ζ-)NP administration was performed to 
observe the localization of fluorescent NPs in the airways at 72 hrs (Figure 2). Both NP 
types were observed throughout the entire lung and most often appear as punctate 
fluorescent regions, presumably internalized into phagocytic cells. These sections were 
stained for CD11c+, finding that the majority of the punctate fluorescence corresponded with 
this surface marker.
To further differentiate the CD11c+ cells visually associated with NPs, we utilized flow 
cytometry to quantify NP uptake in three critical APC lung populations: AM, CD11b DCs 
and CD103 DCs. We sought to explore differences in cell associations of NP and NP-OVA 
formulations of both charges in isolated whole lung cells at 72 hrs following instillation of 
fluorescently-labeled NPs. Ovalbumin (OVA) was used as a model antigen to observe if this 
enhanced uptake. The percentage of NP+ cells indicates how likely a given cell type is to 
associate with any amount of NPs, while the MFI lends insight to how many NPs each 
individual cell internalizes. The total fluorescence was calculated by multiplying the number 
of positive NP cells by the MFI in order to give an overall view of the total volume (related 
to mass) of NPs internalized; the magnitude of this value allows for comparison between NP 
doses and cell types to quantify cellular distribution (Figure 3). Representative gating used 
to analyze these populations is shown in Supplemental Figure 1.
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Alveolar macrophages readily internalized both anionic and cationic NPs (Figure 3A left). 
At the NP dose given, between 60-100% of AMs were NP+. This corresponds well with the 
known function of AM as the primary phagocytic cell in the lung. Interestingly, a greater 
percentage of AM internalized (ζ-)NPs. This is further evident in the MFI and total 
fluorescence intensity (FI) of these cells, as (ζ-)NP-OVA and (ζ-)NP were a factor of 10 
higher than the corresponding (ζ+)NPs (Figure 3A middle, right). This indicates that a single 
AM internalized a significantly greater number of anionic NPs, suggesting that either AM 
have a preference towards internalization of anionic NPs, or the total availability of dosed 
NPs was greater than (ζ+)NPs, presumably due to other clearance methods or non-specific 
binding.
While the AMs showed preference to anionic NPs, both DC subtypes show increased 
association with cationic NPs. Slight increases in NP+ populations were observed following 
(ζ+)NP-OVA and (ζ+)NP administration for CD103 and CD11b DCs (Figure 3B and 3C 
respectively). A greater percentage of CD11b DCs were found to associate with (ζ+)NPs. 
Overall, a greater percentage of CD11b DCs were NP+ as compared to CD103 DCs, 
indicating CD11b DCs found in the lung are more likely to associate with NPs at this time 
point. Interestingly, greater association was observed for non-functionalized NPs, as both 
CD103 and CD11b DCs showed a decrease in (ζ+)NP-OVA association when compared to 
(ζ+)NP. However, both of these groups were higher than anionic formulations. Unlike the 
AM, the MFI of both NP+ CD103 or CD11b DCs were not statistically different across the 
treatment groups, indicating an equivalent amount of NP internalization per cell (Figure 3B 
and C, middle). Compared to AM, the MFI intensity in both DC subtypes was considerably 
lower as well, indicating that DCs in general associated with fewer numbers of NPs. Total 
fluorescence intensity between DC subtypes collected in the lung (Figure 3B and C, right) 
indicates that CD11b DCs in general associate with a greater amount of NPs than CD103 
DCs, with (ζ+)NPs, and (ζ+)NP-OVA to a lesser extent, showing the greatest association.
Effects of Nanoparticle Treatment on Cellular Responses in the Lung
Differences between NP associations with different lung APCs were observed with flow 
cytometry, which can, in part, explain differences previously observed following vaccination 
with these two formulations (8). We further hypothesized that the (ζ+)NP may have an 
adjuvant-like effect in the lung upon administration, which would contribute to production 
of local antibody responses upon vaccination.
To test this, mouse lungs were treated with both NP types and tested for cytokine production 
in the BALF, with PBS and CpG (a toll-like receptor, TLR, 9 agonist) as negative and 
positive controls. The CpG dose delivered was equivalent to previous co-delivery NP-
adjuvant vaccination strategies and served as a qualitative control of known adjuvant activity 
(5, 8). No significant increase in IL-6 (Figure 4A), TNF-α, or IL-1β (not shown) levels in the 
BALF over saline treatment were found at 24 and 72 hrs. This was in stark contrast to the 
effect of CpG administration to the lung, which resulted in ~1000 fold increase in 
inflammatory cytokine production at both time points. Minimal increase, if any, in systemic 
production of these same inflammatory markers was observed for all treatment types (Figure 
4B). This indicates that both formulations of NPs have no increase in local or systemic 
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inflammation over three days, a time point anticipated to be sufficient in capturing the onset 
of acute inflammation. The lack of acute inflammatory responses was corroborated by 
immunohistochemistry staining of NP-treated lungs. H&E staining of representative lung 
histology at 24 hrs (shown in Figure 4C and D) and 72 hrs (not shown), shows no evidence 
of leukocyte recruitment to the lung vasculature. Finally, we tested if (ζ+)NP administration 
would be detrimental to lung function, as previous studies have already shown that (ζ-)NPs 
are well tolerated (32). As shown in Supplemental Figure 2, lungs pretreated with (ζ+)NPs 
maintained the ability to mount an appropriate inflammatory response upon LPS 
stimulation.
While no significant differences in cytokine levels secreted in the BALF were detected, we 
hypothesized that administration of either (ζ+)NP or (ζ-)NP may result in subtle changes in 
cytokine and chemokine production within the lung. At 24 and 72 hrs following instillation, 
whole lungs were homogenized into a single cell suspension to perform qRT-PCR and to 
observe relevant cytokines and chemokines at the mRNA level, normalized to Gapdh (see 
Supplemental Figure 3 for quantified expression). Mice treated with LPS at 24 hrs were 
included as a reference of a known soluble mediator of inflammation; this group was 
excluded from our statistical analysis as it is a qualitative, and not quantitative control, and 
LPS inflammatory responses at the mRNA level are known to have resolved in C57BL/6 
mice within 24 hrs (33). As shown in Figure 5, lungs treated with (ζ+)NPs were found to 
result in significant increased expression over untreated (UT) controls for Ccl2 and Cxcl10 
at both 24 and 72 hrs, as well as increased expression at 24 hrs for Il-10, Il-4, Il-6, Ifn-γ, and 
Il-12β. In these cytokines, mRNA expression had returned to basal expression by 72 hrs, 
indicating an acute and not sustained response to (ζ+)NPs. In contrast, lungs treated with 
(ζ-)NPs showed no increased expression of any of these markers when compared to UT 
controls. No increase in expression was observed from either NP type for Tnf-α (Figure 5), 
Tgfβ-1, or Il-12α (Supplemental Figure 4).
Both Ccl2 and Cxcl10 are important chemo-attractants involved in DC recruitment to the 
lungs (34-36). As these were upregulated in lungs treated with (ζ+)NPs at both 24 and 72 
hrs, we sought to identify changes in lung populations following NP administration after 72 
hrs, allowing for a maximal effect to be detected. Using flow cytometry to differentiate AM 
and DC subtypes as before, we observed relative differences in the total percentage of 
CD45+ leukocytes (Figure 6A), as well as the proportion of DCs between CD11b and 
CD103 subtypes (Figure 6B). Interestingly, there are no statistical differences in the relative 
percentage of AM of total CD45+ cells, but the relative percentage of total DCs increases 
with NP treatment groups, with the greatest increase in the (ζ+)NP-treated group. 
Differences between the composition of the DCs in the lung at this time point are more 
pronounced. Mice administered (ζ+)NP and (ζ+)NP-OVA yielded an increased percentage of 
CD11b DCs in the lung, with a corresponding decrease in CD103 percentage. Anionic 
treatment groups showed considerably less difference, retaining a greater percentage of 
CD103 DCs than the cationic groups. Overall, there was no difference between PBS and 
soluble OVA treated groups, indicating the observed responses were NP-driven.
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Nanoparticle Trafficking to Mediastinal Lymph Nodes
We further hypothesized that the observed changes in lung populations, local changes in 
cytokines and chemokines, and differences in APC-NP association would translate to 
differences in the cellularity and NP frequency in the lung draining LN. 72 hrs after 
instillation, mediastinal LNs were resected and processed to a single cell suspension and 
flow cytometry was used to quantify cell and NP frequencies as in the lung. Representative 
LN gating is shown in Supplemental Figure 5; from this scheme, CD3+ T cells, CD19+ B 
cells, CD11c+ DCs, and CD11b and CD103 DCs were identified. NP association was 
determined as before in each cell population by gating by the PBS-treated, NP FMO control, 
with percentage of NP+ populations, NP+ MFI and total NP+ fluorescence shown in Figure 
7.
NP association with APCs in LN cells was unaffected by lung treatment type at this 72 hr 
time point. Both B and T cells were negative for NP+ following all treatment types (data not 
shown). However, between 10-20% of CD103 DCs (Figure 7A) and 5-10% of CD11b DCs 
(Figure 7B) in the LN were found to be particle positive. However, there were no statistical 
differences found between the NP+ percentage within each DC subtype, nor total 
fluorescence, indicating that NP charge did not influence NP draining to the mediastinal 
lymph node at this time point. Unlike the lung, there were also no observed differences in 
the total cellularity of the lymph nodes, or within DC subtypes (Supplemental Figure 6). 
Macrophage populations were not explored in the draining lymph node, as they are generally 
considered a lung-resident population (12).
DISCUSSION
As pulmonary delivery of nanoparticles continues to be studied as an approach for the next 
generation of vaccines, it will be increasingly important to understand how NP properties 
influence and modify pulmonary immune responses (3, 8). Use of the PRINT platform 
allowed for the same initial particle hydrogel polymerization, NP geometry, crosslinking 
network, amount of functional groups, and composition to isolate NP surface charge as the 
sole variable in these studies. From this, we systematically studied the influence of NP 
surface charge and antigen attachment on lung APC populations, detailing the cellular 
distribution of the NPs, cytokine/chemokine production in the lung, changes in lung APC 
populations, and the propensity to traffic from the lung to the mediastinal LNs. Our results 
show that cationic NPs are preferentially associated with two important lung DC populations 
and increase production of important lung chemo-attractants, which may account for their 
increased efficacy as a pulmonary vaccine carrier.
Cationic NPs preferentially associated with lung DCs, while anionic NPs were more readily 
internalized by AMs. While AMs are considered APCs, their main function in the lung is to 
clear and sequester foreign material and maintain lung homeostasis (12, 16, 17). As a result, 
AMs are not the primary target of NP vaccines and it is more important to target DCs, the 
“professional” APCs. Importantly, anionic NPs sequestered in AMs would be less successful 
at eliciting an adaptive immune response, as uptake in AMs represents an efficient lung 
clearance mechanism. The two lung DC populations studied here have both been implicated 
in critical immune capabilities, including stimulation of IgA production, CD4+ and CD8+ T 
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cell priming, and migration to LNs (11, 12, 16, 20-24). As both CD103 and CD11b DCs 
showed a trend of increased association with cationic NP, it is hypothesized that this 
increased DC association resulted in the previously reported result from our group 
demonstrating improved immune response following vaccination with cationic NPs (8). 
Furthermore, the increased association observed in CD11b DCs may imply an opportunity to 
skew the overall lung immune status, as CD11b DCs have been implicated as a main 
mediator of Th2 lung responses (23, 37). These results demonstrate the importance of NP 
association with lung DCs through manipulation of NP surface chemistry; further cell-
targeted delivery may be possible through variation in alternative NP parameters, such as 
size and surface chemistry (29).
Both NP formulations showed no acute inflammatory response systemically or locally in the 
BALF. However, further characterization of the lungs for mRNA expression of cytokine or 
chemokines showed (ζ+)NP administration upregulated genes for two chemokines, CCL2 
and CXCL10, responsible for leukocyte recruitment (36, 38). We also detected an increase 
in total CD11c+ DCs in the lung following cationic NP administration, likely corresponding 
to the upregulation of these chemokines. Furthermore, the percentage of CD11b DCs from 
total CD11c+ cells increased, likely due to recruitment of this cell type to the lung, and these 
cells were most commonly associated to (ζ+)NPs in the lung. Taken together, these data 
suggest that (ζ+)NP administration to the lung causes recruitment of CD11b DCs to the 
airways, which then preferentially internalize NPs. This increased recruitment and 
association alone may account for increased antibody responses previously observed in our 
group for cationic NPs following pulmonary vaccination, as CD11b cells are the main driver 
of IgA production (24). Increased responses to (ζ+)NP may also have been enhanced by 
upregulation of key Th1 cytokines, such as IFN-γ, Il-6, or Il-12, which can contribute to 
APC activation by 24 hrs (34). It is unclear at this time if this difference in cytokine and 
chemokine production is a result of interactions with the cationic charge on the NP itself or 
differences in the total NPs associated, as (ζ+)NPs were more readily associated with DCs 
than (ζ-)NPs. Aligned with previous studies from our group, (ζ-)NPs were again observed to 
be immunologically inert in the lung (32). Formulations with such anionic NP carriers 
lacking an adjuvant stimulus may result in antigen-specific tolerance, which may offer 
unique therapeutic opportunities (39, 40).
Despite considerable variability in the lung populations and NP cellular association, we do 
not find that changes in the lung environment have affected trafficking to the LN for the time 
point or NP parameters tested. Previous work in the literature has shown the role of NP 
surface charge on passive diffusion from the lung to the LNs, finding that NPs larger than 34 
nm do not rapidly translocate from the lung, regardless of surface charge (41). From both 
whole organ biodistribution, as well as flow cytometry on single cell suspensions of 
mediastinal LNs, NP fluorescence was detected at similar levels for both anionic and 
cationic formulations, confirming some degree of NP trafficking from the lung. Thus, we 
hypothesize that the NPs detected in the LN were actively transported there by lung APCs, 
which can be further confirmed by using carboxyfluorescein succinimidyl ester (CFSE) or 
similar staining to selectively label airway cells prior to migration (11, 42). However, no 
differences were observed in NP association either the LN CD103 DCs, considered to be the 
main migratory lung population (43), or LN CD11b DC populations. These results are in 
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contrast from other routes of particle administration, which demonstrated limited trafficking 
to the local LN of cationic NPs following a foot-pad injection (44). Observation of NP 
trafficking at longer time points, following multiple NP administrations, or further iterations 
of NP parameters may yield larger differences in LN trafficking between NP formulations.
While cationic NPs may not be ideal for an intravenous route of administration, their 
delivery to the lung gives rise to numerous properties which would promote efficacious and 
safe pulmonary vaccine strategies, and may have implications for other mucosal surfaces as 
well. Pulmonary vaccination continues to gain attention as a viable approach to protect 
against wide variety of diseases, especially with increasing developments in dry powder 
administrations (45, 46). This route offers ease of administration and the elimination of 
issues associated with traditionally administered vaccines by eliminating cold chain storage 
issues and requirements for trained personnel for delivery. Additionally, vaccines 
administered via the respiratory tract have demonstrated equivalent or increased local 
protection in the lung to various pathogens, and can also offer systemic and distal mucosal 
protection as well (45, 47). The NPs studied here represent a model particle carrier, which 
can be optimized for a given antigen and route of administration. Our results find that 
cationic formulations offer superior responses specifically in the lung; these NPs can 
promote an environment sufficient to promote antigen-specific responses suitable for 
vaccination, without overt safety concerns. Use of engineered NPs, such as those created 
through the PRINT platform, allows not only for the optimization of the particle carrier to 
pulmonary delivery, as shown here, but can be further adapted to carry a range of antigens 
and antigens to further promote mimicry of the complex pathogen surface (1, 48). This 
approach is expected to increase the range of pathogens capable of being addressed by 
pulmonary vaccination.
Overall, these studies are critical in establishing the role of NP properties on pulmonary 
immune cells, as well as lung APC functions upon particulate exposure. Our findings 
suggest that cationic NPs may offer increased preference towards lung DC subtypes. 
Cationic formulations not only resulted in increased DC association, but modulated the local 
lung environment to promote recruitment and maturation of lung DCs, while avoiding 
extensive AM clearance. In contrast, anionic formulations were found to be 
immunologically inert in the lung, which may offer alternative therapeutic options towards 
promoting tolerance. Our findings demonstrate the importance of particle surface charge in 
pulmonary NP vaccine design and will hopefully contribute to the design of novel vaccines 
towards a wide range of pulmonary pathogens.
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Refer to Web version on PubMed Central for supplementary material.
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LIST OF ABBREVIATIONS
BALF Bronchoalveolar lavage fluid
DC Dendritic cell
AM Alveolar macrophage
NP Nanoparticle
APC Antigen presenting cell
MHC Major histocompatibility complex
LN Lymph node
PRINT Particle replication in non-wetting templates
IACUC Institutional Animal Care and Use Committee
OVA Ovalbumin
LPS Lipopolysaccharide
RT-qPCR Quantitative reverse transcription polymerase chain reaction
FMO Fluorescence minus one
MFI Median fluorescence intensity
ELISA Enzyme-linked immunosorbent assay
H&E Hematoxylin and eosin
FI Fluorescence intensity
TLR Toll-like receptor
CFSE Carboxyfluorescein succinimidyl ester
(ζ+)NP Cationic nanoparticle
Tgf-β1 Transforming growth factor beta one
Tnf-α Tumor necrosis factor alpha
Il Interleukin
Inf-γ Interferon gamma
Cxcl Chemokine (C-X-C motif) ligand
Ccl Chemokine (C-C motif) ligand
Gapdh Glyceraldehyde-3-Phosphate Dehydrogenase
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Figure 1. 
Biodistribution of Instilled Nanoparticles. (A) Representative IVIS imaging. From top to 
bottom: Saline, (ζ+)NP, and (ζ-)NP negative at 24 hrs. Scale bar ranges from 3.14e-4 to 
6.61e-4. (B) Organ distribution of instilled nanoparticles at 24 and 72 hrs. n=4 with bar 
representing SD. Statistics performed by 1-way ANOVA within groups with Tukey multiple 
comparisons test, n.s.
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Figure 2. 
Representative immunohistochemistry of NP-treated lungs after 72 hrs. Sections stained for 
fluorescent NPs (red), phalloidin (gray), DAPI (blue), and CD11c+ (green). (A-C) (ζ+) NPs. 
(D-F) (ζ-) NPs.
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Figure 3. 
NP association in lung APCs. NPs association in (A) AMs, (B) CD103 DCs and (C) CD11b 
DCs from whole lungs of treated C57BL/6 mice after 72 hrs, n≥4 with bar representing SD. 
Within each population, graphs from left to right show the percent NP positive cells, MFI of 
positive cells, and total fluorescence of that cell type. Statistics performed by 1-way ANOVA 
with Tukey multiple comparisons test with *p≤0.05, **p≤0.01, ***p≤0.001. Representative 
gating is found in Supplemental Figure 1.
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Figure 4. 
IL-6 cytokine analysis of (A) BALF and (B) serum following NP and CpG instillation at 24 
and 72 hrs in C57BL/6 mice, n=3 with bar representing SD. Statistics performed by 2-way 
ANOVA with Tukey multiple comparisons test with **p≤0.01, ***p≤0.001. (C & D) H&E 
stained whole lung sections of NP treated lungs at three magnifications: (C) shows (ζ+)NP 
treated and (D) shows (ζ-)NP treated at 24 hrs following NP instillation with scale bars 
(from top to bottom) of 500 μm, 100 μm, and 50 μm, respectively.
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Figure 5. 
qRT-PCR for mRNA expression of Ccl2, Il-10, Il-4, Il-6, Cxcl10, Ifn-γ, Il-12β, and Tnf-α by 
single cell suspensions of lung cells treated with either (ζ+)NP or (ζ-)NP and homogenized 
at 24 hrs and 72 hrs. Data are normalized to GADPH mRNA (quantity shown in 
Supplemental Figure 3) and graphed as fold change over UT. UT and LPS treatments shown 
for 24 hrs. n=4 with bar representing SD. Statistics performed by 1-way ANOVA with 
Dunnet's multiple comparisons test to UT control with *p≤0.05, **p≤0.01, ***p≤0.001 and 
LPS groups excluded from statistical analysis.
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Figure 6. 
APC populations in the lung following NP treatment. (A) APC population breakdown of 
DCs and APCs in the whole lungs of treated C57BL/6 mice after 72 hrs, n≥4 with bar 
representing SD. Populations stacked and not overlaid, such that bar magnitude as shown 
represents the sum of two cell populations. Statistics performed by 1-way ANOVA with 
Dunnet's multiple comparisons test to PBS treatment. *indicate significant difference within 
DCs with *p≤0.05, **p≤0.01, ***p≤0.001, AM n.s between groups. Populations stacked. 
(B) Subtypes of CD11c+ DCs in the whole lungs of treated C57BL/6 mice after 24 hrs, n≥4 
with bar representing SD. Statistics performed by 1-way ANOVA with Dunnet's multiple 
comparisons test to PBS treatment. * indicate significant difference within CD11b DCs 
compared to PBS with *p≤0.05, **p≤0.01, ***p≤0.001 and # indicate significant difference 
within CD103 DCs compared to PBS with #p≤0.05, ##p≤0.01, ###p≤0.001. Representative 
gating is found in Supplemental Figure 1.
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Figure 7. 
NP association in LN DCs. NPs association in (A) CD103 DCs, and (B) CD11b DCs from 
mediastinal LNs of treated C57BL/6 mice after 72 hrs, n≥4 with bar representing SD. Within 
each population, graphs from left to right show the percent NP positive cells, MFI of positive 
cells, and total fluorescence of that cell type. Statistics performed by 1-way ANOVA with 
Tukey multiple comparisons test with *p≤0.05. Representative gating is found in 
Supplemental Figure 5.
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